Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2017

View Archived Issues

Novartis reports key developments of first quarter 2017

New phase III trial explores use of simvastatin in children with Noonan syndrome

Xenon acquires potassium channel modulator for the treatment of epilepsy

Sage Therapeutics begins phase I development of SAGE-718

FDA grants breakthrough therapy designation to lorlatinib for ALK-positive metastatic NSCLC

Aldeyra initiates phase III study of ADX-102 for noninfectious anterior uveitis

ProQR Therapeutics cleared to begin phase I/II study of QR-110 in LCA 10

RCM-1 reduces lung inflammation in response to HDM and recombinant IL-13 in vivo

Promising interim phase I results for autologous EBV-specific T-cell therapy for MS

Amgen profiles pipeline progress of first quarter 2017

FOCUS results show promise of dimethyl fumarate in pediatric relapsing-remitting MS

Preclinical efficacy of novel HBV expression inhibitor RG-7834 in combination therapy

FDA approves Brineura to treat CLN2 disease

New mouse model of acute alcoholic hepatitis developed

Cellectar reports preclinical data on CLR-131 and CLR-125

FDA approves Stivarga for second-line treatment of hepatocellular carcinoma

Wnt signaling inhibitors patented by Suzhou Yunxuan Yiyao Keji Youxian Gongsi

Inventiva discovers novel YAP/TEAD interaction inhibitors

Pfizer seeks Japanese approval for inotuzumab ozogamicin in ALL

Polyphor synthesizes new Pin1 inhibitors

Universite Pierre et Marie Curie and collaborators identify novel RIP-1 inhibitors

BridgeBio launches Eidos Therapeutics to develop AG-10 for TTR amyloidosis

Sichuan Haisco describes novel muscarinic M3 antagonists and/or beta2-adrenergic receptor agonists

Shanghai Hengrui and Jiangsu Hengrui Medicine discover mu-opioid receptor agonists

Tavalisse accepted as proprietary name for fostamatinib disodium in U.S.

Myriad Genetics and Clovis Oncology enter companion diagnostic collaboration for Rubraca

Antibe Therapeutics begins IND-enabling preclinical studies for analgesic ATB-352

New TLR5 polymorphism found to be associated with HCC in chronic hepatitis B patients

Savara closes merger with Mast Therapeutics

Agios and Aurigene in license agreement on small-molecule inhibitors of cancer metabolism target

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...